Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1 / Phase 2	2024-07-16		NCT06503107

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hebei Taihe Chunyu Biotechnology Co., Ltd	14
Huazhong University of Science and Technology Union Shenzhen Hospital	4
The Seventh Affiliated Hospital of Sun Yat-sen University	6
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	77